Stockreport

Takeda Announces U.S. FDA Breakthrough Therapy Designation for Mobocertinib (TAK-788) for the Treatment of NSCLC Patients with EGFR Exon 20 Insertion Mutations

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)

More Company Research Source: Business Wire

PDF – Designation Represents Positive Progress for a Unique Patient Population in Need of Targeted Therapy Options CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Take [Read more]

EVENT DAY Stock performance from the time of news release until the following 4pm ET market close	LAST PRICE AT NEWS EVENT {{SecondSection.LastPriceAtNewsEvent}}	SINCE EVENT Multi-day stock performance from the time of the news release
{{FirstSection.LastPrice}}	LAST PRICE	{{SecondSection.LastPrice}}
{{FirstSection.VWapStr_AMP}} {{FirstSection.VwapEventTime}}	VWAP	{{SecondSection.VWapStr_AMP}} {{SecondSection.VwapEventTime}}
{{FirstSection.MaxUp}} High: {{FirstSection.EodHigh}}	MAX UP	{{SecondSection.MaxUp}} High: {{SecondSection.EodHigh}}
{{FirstSection.MaxDown}} Low: {{FirstSection.EodLow}}	MAX DOWN	{{SecondSection.MaxDown}} Low: {{SecondSection.EodLow}}
{{FirstSection.TodaysRangeStr_AMP}} {{FirstSection.RangEvg}}	POST NEWS RANGE	{{SecondSection.TodaysRangeStr_AMP}} {{SecondSection.RangEvg}}
{{FirstSection.PriceChange}} {{FirstSection.PriceChangeTriangle_AMP}}	PRICE CHANGE	{{SecondSection.PriceChange}} {{SecondSection.PriceChangeTriangle_AMP}}
{{FirstSection.PriceChangePercent}}	PRICE CHANGE PERCENTAGE	{{SecondSection.PriceChangePercent}}
{{FirstSection.Spx500}}	S&P 500 (SPX)	{{SecondSection.Spx500}}
{{FirstSection.VolumeImpactStr_AMP}}	VOLUME RATIO	{{SecondSection.VolumeImpactStr_AMP}}
{{FirstSection.Volume}}	VOLUME (SHARES)	{{SecondSection.Volume}}
{{FirstSection.TicksString}}	TICKS	{{SecondSection.TicksString}}
{{FirstSection.AvgTransactionSizeStr_AMP}}	AVG SHARES PER TRADE	{{SecondSection.AvgTransactionSizeStr_AMP}}

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Takeda Announces U.S. FDA Breakthrough Therapy Designation for Mobocertinib (TAK-788) for the Treatment of NSCLC Patients with EGFR Exon 20 Insertion Mutations

{{GreenBoxData.Blurb}}

Opt in for alerts from News Quantifed